Are adverse outcome pathways here to stay?

Environmental Science and Technology

Volumn 49, Issue 1, 2015, Pages 3-9

  Garcia Reyero, Natàlia ^a  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL COMMUNITY; HEALTH CARE; HEALTH POLICY; PUBLIC HEALTH; SOCIAL IMPACT; TESTING METHOD; TOXICOLOGY;

ADVERSE OUTCOME; ADVERSE OUTCOME PATHWAY; ARTICLE; CHRONIC TOXICITY; CLINICAL PATHWAY; DECISION MAKING; ECOTOXICOLOGY; ENVIRONMENTAL PROTECTION; HUMAN; IN VITRO STUDY; LINEAR SYSTEM; NONHUMAN; QUANTITATIVE STUDY; RESEARCH PRIORITY; RISK ASSESSMENT; SYSTEMS BIOLOGY; TOXICITY TESTING; WORLD HEALTH ORGANIZATION; ADVERSE DRUG REACTION; ANIMAL; PROCEDURES; THEORETICAL MODEL; TRENDS;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECOTOXICOLOGY; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84924981770     PISSN: 0013936X     EISSN: 15205851     Source Type: Journal    
DOI: 10.1021/es504976d     Document Type: Article

References (38)

1. Krewski, D.; Acosta, D.; Andersen, M.; Anderson, H.; Bailar, J. C.; Boekelheide, K.; Brent, R.; Charnley, G.; Cheung, V. G.; Green, S.; et al. Toxicity testing in the 21st century: A vision and a strategy. J. Toxicol. Environ. Health, Part B 2010, 13, 51-138.
2. Villeneuve, D. L.; Garcia-Reyero, N. Vision &strategy: Predictive ecotoxicology in the 21st century. Environ. Toxicol. Chem. 2011, 30, 1-8.
3. Perkins, E. J.; Ankley, G. T.; Crofton, K. M.; Garcia-Reyero, N.; Lalone, C. A.; Johnson, M. S.; Tietge, J. E.; Villeneuve, D. L. Current perspectives on the use of alternative species in human health and ecological hazard assessments. Environ. Health Perspect 2013, 121, 1002-1010.
4. NRC. Toxicity testing in the 21st century. In A Vision and a Strategy; The National Academies Press: Washington DC, 2007.
5. Ankley, G. T.; Bennett, R. S.; Erickson, R. J.; Hoff, D. J.; Hornung, M. W.; Johnson, R. D.; Mount, D. R.; Nichols, J. W.; Russom, C. L.; Schmieder, P. K.; et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29, 730-741.
6. Volz, D. C.; Belanger, S.; Embry, M.; Padilla, S.; Sanderson, H.; Schirmer, K.; Scholz, S.; Villeneuve, D. L. Adverse outcome pathways during early fish development: A conceptual framework for identification of chemical screening and prioritization strategies. Toxicol. Sci. 2011, 123, 349-358.
7. Boobis, A. R.; Cohen, S. M.; Dellarco, V.; McGregor, D.; Meek, M. E. B.; Vickers, C.; Willcocks, D.; Farland, W. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit. Rev. Toxicol. 2006, 36, 781-792.
8. Boobis, A. R.; Doe, J. E.; Heinrich-Hirsch, B.; Meek, M. E. B.; Munn, S.; Ruchirawat, M.; Schlatter, J.; Seed, J.; Vickers, C. IPCS Framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev. Toxicol 2008, 38, 87-96.
9. Watanabe, K. H.; Andersen, M. E.; Basu, N.; Carvan, M. J.; Crofton, K. M.; King, K. A.; Suñol, C.; Tiffany-Castiglioni, E.; Schultz, I. R. Defining and modeling known adverse outcome pathways: Domoic acid and neuronal signaling as a case study. Environ. Toxicol. Chem. 2011, 30, 9-21.
10. Perkins, E. J.; Chipman, J. K.; Edwards, S.; Habib, T.; Falciani, F.; Taylor, R.; Van Aggelen, G.; Vulpe, C.; Antczak, P.; Loguinov, A. Reverse engineering adverse outcome pathways. Environ. Toxicol. Chem. 2011, 30, 22-38.
11. Nichols, J. W.; Breen, M.; Denver, R. J.; Distefano, J. J.; Edwards, J. S.; Hoke, R. A.; Volz, D. C.; Zhang, X. Predicting chemical impacts on vertebrate endocrine systems. Environ. Toxicol. Chem. 2011, 30, 39-51.
12. Kramer, V. J.; Etterson, M. A.; Hecker, M.; Murphy, C. A.; Roesijadi, G.; Spade, D. J.; Spromberg, J. A.; Wang, M.; Ankley, G. T. Adverse outcome pathways and ecological risk assessment: Bridging to population-level effects. Environ. Toxicol. Chem. 2010, 30, 64-76.
13. Celander, M. C.; Goldstone, J. V.; Denslow, N. D.; Iguchi, T.; Kille, P.; Meyerhoff, R. D.; Smith, B. A.; Hutchinson, T. H.; Wheeler, J. R. Species extrapolation for the 21st century. Environ. Toxicol. Chem. 2011, 30, 52-63.
14. OECDGuidance document on developing and assessing adverse outcome pathways. In Series on Testing and Assessment, ENV/JM/ MONO(2013)6, no. 184, 2013; pp 145.
15. Groh, K. J.; R, C.; Chipman, J. K.; Denslow, N. D.; Halder, M.; Murphy, C. A.; Roelofs, D.; Rolaki, A.; Schirmer, K.; Watanabe, K. H. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: II. A focus on growth impairment in fish. Chemosphere 2014, 120, 778-792.
16. Groh, K. J.; Carvalho, R.; Chipman, J. K.; Denslow, N. D.; Halder, M.; Murphy, C. A.; Roelofs, D.; Rolaski, A.; Schirmer, K.; Watanabe, K. H. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology. Chemosphere 2014, 120, 764-777.
17. Villeneuve, D.; Crump, D.; Garcia-Reyero, N.; Hecker, M.; Hutchinson, T. H.; Lalone, C. A.; Landersmann, B.; Lettieri, T.; Munn, S.; Nepelska, M.; et al. Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicol. Sci. 2014, 142, 312-320.
18. Villeneuve, D.; Crump, D.; Garcia-Reyero, N.; Hecker, M.; Hutchinson, T. H.; Lalone, C. A.; Landesmann, B.; Lettieri, T.; Munn, S.; Nepelska, M.; et al. Adverse outcome pathway (AOP) development II: Best practices. Toxicol. Sci. 2014, 142, 312-320.
19. Perkins, E. J.; Antczak, P.; Burgoon, L. D.; Falciani, F.; Garcia-Reyero, N.; Gutsell, S.; Hodges, G.; Kienzler, A.; Knapen, D.; McBride, M.; et al. Using adverse outcome pathways for regulatory applications; Toxicol. Sci., 2014 (submitted).
20. Tollefsen, K. E.; Scholz, S.; Cronin, M. T.; Edwards, S. W.; de Knecht, J.; Crofton, K.; Garcia-Reyero, N.; Hartung, T.; Worth, A.; Patlewicz, G. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul. Toxicol. Pharmacol. 2014, 1-12.
21. Hill, A. B. The environment and disease: Association or causation? Proc. R. Soc. Med. 1965, 58, 295.
22. Meek, M. E.; Boobis, A.; Cote, I.; Dellarco, V.; Fotakis, G.; Munn, S.; Seed, J.; Vickers, C. New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J. Appl. Toxicol 2014, 34, 1-18.
23. Meek, B.; Renwick, A.; Sonich-Mullin, C. International Programme on Chemical Safety. Practical application of kinetic data in risk assessment-An IPCS initiative. Toxicol. Lett. 2003, 138, 151-160.
24. Villeneuve, D.; Volz, D. C.; Embry, M. R.; Ankley, G. T.; Belanger, S. E.; Léonard, M.; Schirmer, K.; Tanguay, R.; Truong, L.; Wehmas, L. Investigating Alternatives to the fish early-life stage test: A strategy for discovering and annotating adverse outcome pathways for early fish development. Environ. Toxicol. Chem. 2014, 33, 158-169.
25. Perkins, E. J.; Antczak, P.; Burgoon, L. D.; Falciani, F.; Garcia-Reyero, N.; Gutsell, S.; Hodges, G.; Kienzler, A.; Knapen, D.; McBride, M. Quantitative adverse outcome pathways for regulatory applications Toxicol. Sci. 2014, (submitted).
26. Gunnarsson, L.; Jauhiainen, A.; Kristiansson, E.; Nerman, O.; Larsson, D. G. J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessments. Environ. Sci. Technol. 2008, 42, 5807-5813.
27. Kostich, M. S.; Lazorchak, J. M. Risks to aquatic organisms posed by human pharmaceutical use. Sci. Total Environ. 2008, 389, 329-339.
28. Bauer-Mehren, A.; Furlong, L. I.; Sanz, F. Pathway databases and tools for their exploitation: Benefits, current limitations and challenges. Mol. Syst. Biol. 2009, 5, -.
29. Burgess-Herbert, S. L.; Euling, S. Y. Use of comparative genomics approaches to characterize interspecies differences in response to environmental chemicals: Challenges, opportunities, and research needs. Toxicol. Appl. Pharmacol. 2013, 271, 372-385.
30. Cote, I.; Anastas, P. T.; Birnbaum, L. S.; Clark, R. M.; Dix, D. J.; Edwards, S. W.; Preuss, P. W. Advancing the next generation of health risk assessment. Environ. Health Perspect 2012, 120, 1499-1502.
31. Willett, C.; Caverly Rae, J.; Goyak, K. O.; Landesmann, B.; Minsavage, G.; Westmoreland, C. Pathway-based toxicity: History, current approaches and liver fibrosis and steatosis as prototypes. ALTEX 2014, 31, 407-421.
32. Willett, C. Building shared experience to advance practical application of pathway-based toxicology: Liver toxicity mode-of-Action. ALTEX 2014, 31, 500-519.
33. Collins, F. S.; Gray, G. M.; Bucher, J. R. Transforming environmental health protection. Science 2008, 319, 907-907.
34. Kavlock, R.; Chandler, K.; Houck, K.; Hunter, S.; Judson, R.; Kleinstreuer, N.; Knudsen, T.; Martin, M.; Padilla, S.; Reif, D.; et al. Update on EPA's ToxCast program: Providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol. 2012, 25, 1287-1302.
35. Kleinstreuer, N. C.; Yang, J.; Berg, E. L.; Knudsen, T. B.; Richard, A. M.; Martin, M. T.; Reif, D. M.; Judson, R. S.; Polokoff, M.; Dix, D. J.; et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 2014, 32, 583-591.
36. Carvunis, A.-R.; Ideker, T. Siri of the cell: What biology could learn from the iPhone. Cell 2014, 157, 534-538.
37. Forbes, V. E.; Calow, P. Is the per capita rate of increase a good measure of population-level effects in ecotoxicology? Environ. Toxicol. Chem. 1999, 18, 1544-1556.
38. Forbes, V. E.; Calow, P. Promises and problems for the new paradigm for risk assessment and an alternative approach involving predictive systems models. Environ. Toxicol. Chem. 2012, 31, 2663-2671.